Browse RMM Directory A-Z

${pdf_link}$

Cablivi 10 mg powder and solvent for solution for injection – Patient Card - Risk Minimisation Information for Patients

This Patient Alert Card has been developed for prescribers and healthcare professionals (HCPs) involved in the care of patients treated with Cablivi (caplacizumab), to provide further information about the potential serious risks associated with the use of this medicine. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Caffeine Citrate 10mg/ml laminated card

Caffeine Citrate 10m/ml Solution for Injection and Oral Solution laminated card

${pdf_link}$

UK Camzyos (mavacamten) Healthcare Professional Checklist

This risk minimisation material is a condition of the marketing authorisation. This Checklist supports the communication of critical tasks and actions throughout the patient’s cycle of treatment with mavacamten; before starting treatment, during treatment, and after treatment has been discontinued.

${pdf_link}$

UK Camzyos (mavacamten) Patient Card

This risk minimisation material is a condition of the marketing authorisation. It supports the communication of critical safety measures, including notifying your doctor if you experience symptoms of heart failure, not starting or stopping any medications without talking to your doctor, and avoiding pregnancy. Please ensure that you carry this card with you at all times.

${pdf_link}$

UK Camzyos (mavacamten) Patient Guide

This risk minimisation material is a condition of the marketing authorisation. It supports the communication of critical safety measures, including notifying your doctor if you experience symptoms of heart failure, not starting or stopping any medications without talking to your doctor, and avoiding pregnancy. Embryo-fetal toxicity risk information is presented as a tear-out in the Patient Guide, which can be removed if the risk of embryo-fetal toxicity does not apply.

${pdf_link}$

Caprelsa-Healthcare Professional (HCP) Guide - Risk Minimisation Information for Healthcare Professionals

For hard copies, please contact medical information department at 0800 035 2525 or email [email protected].

${pdf_link}$

Caprelsa-Patient Alert Card

For hard copies, please contact medical information department at 0800 035 2525 or email [email protected]

${pdf_link}$

Caprelsa-Patient Guide - Risk Minimisation Information for Patients

For hard copies, please contact medical information department at 0800 035 2525 or email [email protected].

${pdf_link}$

Carvykti Handling Guide

CAR-T handling guide

${pdf_link}$

Carvykti Healthcare Professional Information

information for CAR-T centre healthcare professionals

${pdf_link}$

Carvykti Patient Information

My CAR-T journey (information for patients)

${pdf_link}$

CASGEVY Guide for Patients and Carers

Important information about CASGEVY for patients and carers

${pdf_link}$

CASGEVY Handling and Administration Guide

Important information for Healthcare Professionals about CASGEVY

${pdf_link}$

CASGEVY Patient Alert Card

Important information for patients regarding CASGEVY

${pdf_link}$

CellCept: Guide for Healthcare Professionals

This material is provided by Roche Products Ltd and forms part of the licence requirement. Please ensure that you are familiar with this material as it contains important safety information

${pdf_link}$

CellCept: Guide for Patients

This material is provided by Roche Products Ltd as a licence requirement. Please ensure that you are familiar with this material as it contains important safety information.

${pdf_link}$

Healthcare Provider Guide

This guide details the risk of teratogenicity.

${pdf_link}$

Patient Guide

This guide details the risks of miscarriage and birth defects.

${pdf_link}$

CERDELGA (eliglustat) Patient Alert card

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

CERDELGA (eliglustat) Prescriber Guide

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Cerezyme (imiglucerase) - Home Infusion HCP Manual - Risk Minimisation Information for Healthcare Professionals

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Cerezyme (imiglucerase) at home. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Cerezyme (imiglucerase) - Home Infusion Patient Manual - Risk Minimisation Information for Patients

The objective of this document is to provide patients with guidance on how to receive Cerezyme (imiglucerase) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Cialis Together - Check list

This Pharmacist Checklist Quick Guide is provided to assist you in your assessment of a patient’s suitability for Cialis Together. It is designed to be used in conjunction with the Cialis Together Checklist. The Cialis Together Checklist can be provided to the patient to complete before consultation with you or it can be used as part of your consultation with the patient. Use of this material is optional and pharmacists should use their professional judgement to decide when and how to use it.

${pdf_link}$

Cialis Together - Check list Quick Guide

This Pharmacist Checklist Quick Guide is provided to assist you in your assessment of a patient’s suitability for Cialis Together. It is designed to be used in conjunction with the Cialis Together Checklist. The Cialis Together Checklist can be provided to the patient to complete before consultation with you or it can be used as part of your consultation with the patient. Use of this material is optional and pharmacists should use their professional judgement to decide when and how to use it.

${pdf_link}$

Cialis Together - Pharmacy guide

This guide, together with the Cialis Together checklist and Pharmacist Checklist Quick guide (which helps with the interpretation of patients' answers), has been developed by Sanofi to support pharmacists and pharmacy assistants in managing the risks related to Cialis Together and enabling its appropriate supply and use.

${pdf_link}$

Cialis Together - Repeat Purchase Referral Card

After assessing the man, using the Cialis Together Pharmacist Checklist Quick Guide, complete and supply them with either the Repeat Purchase Card or Referral Card by tearing off the appropriate card.

${pdf_link}$

Cibinqo (abrocitinib) Patient Card

Description: Cibinqo Patient Card

${pdf_link}$

Cibinqo (abrocitinib) Prescriber Brochure

Description: Prescriber brochure to provide guidance on assessments prior to prescribing, management, monitoring and safety considerations related to the Risk Management Plan

${pdf_link}$

Checklist for Prescribers

Checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.

${pdf_link}$

Cilique Patient User Card

Important information for women about risk of blood clots with combined hormonal contraceptives (CHC).

${pdf_link}$

Checklist for Prescribers - Cimizt 150 microgram/30 microgram Tablets

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations. •Thromboembolism (e.g. deep vein thrombosis, pulmonary embolism, heart attack and stroke) is a rare but important risk with use of a CHC.

${pdf_link}$

Important Information for Women Leaflet - Cimizt 150 microgram/30 microgram Tablets

All women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.

${pdf_link}$

Patient Alert Card - Cimizt 150 microgram/30 microgram Tablets

IMPORTANT INFORMATION FOR WOMEN ABOUT RISK OF BLOOD CLOTS WITH COMBINED HORMONAL CONTRACEPTIVES

${pdf_link}$

Cimzia Patient Alert card

This alert card contains important safety information that patients need to be aware of before they are given CIMZIA and during treatment with CIMZIA.

${pdf_link}$

Cinryze▼(Human C1-esterase inhibitor) Patient Diary

Cinryze Patient Diary

${pdf_link}$

Cinryze®▼ (Human C1-esterase inhibitor) HCP guide

Cinryze HCP Guide

${pdf_link}$

Cinryze®▼ (Human C1-esterase inhibitor) Patient guide

Cinryze Patient Guide

${pdf_link}$

Checklist for Prescribers - Teragezza

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations. Cyproterone acetate and ethinylestradiol tablet are used for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age.

${pdf_link}$

Important Information for Women - Teragezza

The review recommended that all women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.

${pdf_link}$

Patient Alert Card - Teragezza

Risk of blood clots with combined hormonal contraceptives. All combined contraceptives increase the rare but important risk of having a blood clot. It is important to recognise the signs and symptoms to look out for and what action to take.

${pdf_link}$

Columvi®▼(glofitamab) Healthcare Professional Guide

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Patient Card: Important Safety Information for Patients receiving Columvi®▼(glofitamab)

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

${pdf_link}$

Valproate - “White Box” Warning Labels

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products.. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate - Healthcare professionals (HCPs) Guide - Pregnancy Prevention Programme

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate - Patient Card - Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate - Patient Guide

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate - Poster - Dispensary - Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

${pdf_link}$

Valproate Female Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

${pdf_link}$

Risk Minimisation Materials

Cablivi

SANOFI

Caffeine

Martindale Pharma, an Ethypharm Group Company

Camzyos

Bristol Myers Squibb Pharmaceuticals limited

Caprelsa

SANOFI

CARVYKTI

Janssen-Cilag Ltd (a Johnson & Johnson Company)

Casgevy

Vertex Pharmaceuticals (Europe) Limited

Cellcept

Roche Products Limited

Ceptava

Sandoz Limited

Cerdelga

SANOFI

Cerezyme

SANOFI

Cialis

SANOFI Consumer Healthcare

Cibinqo

Pfizer Limited

Cilique

Gedeon Richter (UK) Ltd

Cimizt

Morningside Healthcare Ltd

Cimzia

UCB Pharma Limited

Cinryze

Takeda UK Ltd

Co-cyprindiol

Morningside Healthcare Ltd

Columvi

Roche Products Limited

Convulex

G.L Pharma UK Limited

Cordarone

Zentiva

CosmoFer

Pharmacosmos UK Limited

You are trying to reach document intended for healthcare professionals only.